Clinical trial · Interventional
Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin
Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome and Acute Myeloid Leukaemia Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): FB ATG is now a standard for sib allo MDS patients
Summary
Brief summary (as posted)
The purpose of this study is to determine the safety and feasibility of conditioning with fludarabine, busulphan and thymoglobuline in patients with myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative disorders (MDS/MPD) or acute myeloid leukaemia (AML) undergoing haematopoietic stem cell allograft with granulocyte colony-stimulating factor (G-CSF)-mobilised peripheral blood stem cells (PBSC) (or bone marrow) from HLA compatible sibling donors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Myeloid, Acute | Leukemia | ONTOLOGY_EXACT | 0.85 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Busulphan | Drug | — | UNRESOLVED |
| Fludarabine | Drug | Fludarabine | ALIAS |
| Haematopoietic stem cell infusion | Procedure | — | UNRESOLVED |
| Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- FBATG
- description
- Haematopoietic stem cell transplantation utilising conditioning with Fludarabine, Busulphan and Thymoglobuline
- interventionNames
- Drug: Fludarabine
- Drug: Busulphan
- Drug: Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme
- Procedure: Haematopoietic stem cell infusion
Primary outcomes (1)
- measure
- Treatment related mortality to Day 100
- timeFrame
- Days 28, 56 and 100
Secondary outcomes (7)
- measure
- Incidence of single or multi-organ acute toxicity
- timeFrame
- Days 28, 56 and 100
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Patient Selection 1. Availability of a HLA compatible sibling donor 2. Age \>18 years 3. Myelodysplastic Syndromes with IPSS Intermediate-2 or High. 4. Poor risk acute myeloid leukaemia, de novo or transformed from MDS 5. Ineligibility for standard conditioning allograft due to age or co-existing morbidities Donor selection 1\. Related donors compatible for HLA-A, B, C, DRB1 and DQB1 by molecular typing. Exclusion Criteria: Patient selection 1. Cardiac insufficiency requiring treatment or symptomatic coronary artery disease. 2. Hepatic disease, with AST \> 2 times normal. 3. Severe hypoxaemia, pO2 \< 70 mm Hg, with decreased DLCO \< 70% of predicted; or mild hypoxemia, pO2 \< 80 mm Hg with severely decreased DLCO \< 60% of predicted. 4. Impaired renal function (creatinine \> 2 times upper limit of normal or creatinine clearance \< 50% for age, gender, weight). 5. Patients who have received previous treatment with Thymoglobuline 6. HIV-positive patients. 7. Female patients who are pregnant or breast feeding due to risks to foetus from conditioning regimen and potential risks to nursing infants. 8. Life expectancy severely limited by diseases other than MDS or MPD. 9. Serious concurrent untreated infection 10. Patients with limited life expectancy for other reasons 11. Serious psychiatric/ psychological disorders 12. Absence of /inability to provide informed consent Donor selection 1. Age \>75 years, unless independently assessed to be medically fit to donate 2. Donors who for any reason are unable to tolerate the leukapheresis procedure and cannot undergo anaesthesia for marrow harvest. 3. Donors who are HIV-positive, or hepatitis B or C PCR positive. 4. Donors who are medically unsuitable to donate
References
Publications (0)
Data not yet available